Open this publication in new window or tab >>2026 (English)Doctoral thesis, comprehensive summary (Other academic)
Lungemboli bortom det akuta skedet : långvariga symtom, följdtillstånd och överlevnad
Abstract [en]
Pulmonary embolism (PE) is a common cardiovascular disease associated with substantial short- and long-term morbidity. Chronic thromboembolic pulmonary hypertension (CTEPH) is a serious but uncommon long-term complication, while a considerably larger proportion of patients experience persistent dyspnoea, exercise limitation, and impaired health status after PE. These manifestations, together with persistent cardiopulmonary abnormalities, are increasingly described within the concept of post-pulmonary embolism syndrome (PPES), which encompasses a heterogeneous spectrum ranging from functional impairment without an identified cardiopulmonary cause to chronic thromboembolic pulmonary disease (CTEPD) and CTEPH. However, the extent to which symptoms and abnormalities detected after PE represent consequences of the preceding embolic event, reflect underlying comorbidity, or constitute clinically meaningful pulmonary vascular disease remains uncertain. The overall aim of this thesis was to investigate long-term symptoms, cardiopulmonary abnormalities, and survival after PE, and to examine their relationships and clinical significance.
The first study examined the prevalence of dyspnoea in a nationwide cohort of Swedish PE survivors and compared them with a population-based control cohort. At a median of 3.4 years after PE, dyspnoea was markedly more common among PE survivors than among controls. The association between previous PE and dyspnoea remained significant after adjustment for age, sex, smoking habits, and multiple comorbidities, demonstrating a substantial long-term symptom burden associated with previous PE that was not explained by the measured comorbidities and other potential confounders.
The second study investigated electrocardiographic abnormalities and plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels among PE survivors selected because of dyspnoea or risk factors for chronic thromboembolic disease. Although abnormal electrocardiograms and elevated NT-proBNP levels were common, findings specifically suggestive of right ventricular dysfunction were infrequent. Neither electrocardiographic markers of right ventricular strain nor NT- proBNP levels were independently associated with dyspnoea severity. These findings suggest that the value of ECG and NT- proBNP in long-term follow-up after PE may primarily lie in differential diagnosis rather than in identifying a PE-specific cause of persistent dyspnoea.
The third study assessed whether dyspnoea at long-term follow-up after PE was associated with mortality. Although dyspnoea was associated with reduced survival in unadjusted analyses, it was not independently associated with mortality after adjustment for age, sex, smoking, and time-dependent comorbidities. Exploratory analyses suggested possible differences by sex and age, with dyspnoea being associated with increased mortality among men but not women, while age- stratified analyses showed no consistent pattern. No association between dyspnoea and mortality was observed in the population-based reference cohort.
The fourth study evaluated late perfusion defects assessed by ventilation–perfusion scintigraphy several years after the index PE. Perfusion defects were common and were associated with reduced survival in unadjusted analyses. However, after adjustment for age and comorbidities in inverse probability-weighted analyses, perfusion defects were not independently associated with long-term mortality. Furthermore, no association was observed between perfusion defects and dyspnoea severity. These findings suggest that the apparent prognostic impact of late perfusion defects largely reflects underlying patient characteristics rather than an independent effect.
In conclusion, dyspnoea and objective cardiopulmonary abnormalities are common at long-term follow-up after PE. However, the relationships between previous PE, persistent symptoms, objective abnormalities, and long-term prognosis are complex. Neither dyspnoea nor late perfusion defects were independently associated with mortality after accounting for age and comorbidities, and late perfusion defects were not associated with dyspnoea severity. Taken together, the findings do not support a simple model in which post-PE dyspnoea or late perfusion defects necessarily represent persistent PE- related disease. Future studies should better distinguish PE-related disease from comorbidity and other causes of long-term symptoms and abnormalities, and determine which findings identify clinically meaningful and potentially treatable disease. From a clinical perspective, persistent dyspnoea after PE should prompt an aetiologically open assessment in which potentially treatable pulmonary vascular disease is considered alongside cardiac and pulmonary comorbidity, deconditioning, and other causes of functional limitation. Similarly, late perfusion defects should not be interpreted in isolation as evidence that persistent thromboembolic disease explains a patient’s symptoms or prognosis.
Keywords: Pulmonary embolism, post-pulmonary embolism syndrome, NT-proBNP, ECG, chronic thromboembolic pulmonary disease, dyspnoea, mortality
Place, publisher, year, edition, pages
Umeå: Umeå University, 2026. p. 95
Series
Umeå University medical dissertations, ISSN 0346-6612 ; 2453
Keywords
Pulmonary embolism, post-pulmonary embolism syndrome, NT-proBNP, ECG, chronic thromboembolic pulmonary disease, dyspnoea, mortality
National Category
Respiratory Medicine and Allergy Cardiology and Cardiovascular Disease
Research subject
Internal Medicine
Identifiers
urn:nbn:se:umu:diva-261423 (URN)978-91-6850-159-8 (ISBN)978-91-6850-160-4 (ISBN)
Public defence
2026-11-27, Sal A1, Norrlands universitetssjukhus, byggnad 1D, vån 9, Umeå, 09:00 (Swedish)
Opponent
Supervisors
Projects
CTEPH-projektet
Note
Link to participate via Zoom: https://umu.zoom.us/j/62878331943?pwd=Tm0reC9LdDVrM1NoQjFjTS85YUZFZz09, password: 112233.
2026-11-062026-10-302026-11-04Bibliographically approved